- Home
- IPSC vs LTRN Comparison
IPSC vs LTRN Comparison
Compare IPSC & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- LTRN
- Stock Information
- Founded
- IPSC 2019
- LTRN 2013
- Country
- IPSC United States
- LTRN United States
- Employees
- IPSC N/A
- LTRN N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- LTRN Health Care
- Exchange
- IPSC Nasdaq
- LTRN Nasdaq
- Market Cap
- IPSC 49.1M
- LTRN 49.9M
- IPO Year
- IPSC 2021
- LTRN 2020
- Fundamental
- Price
- IPSC $0.56
- LTRN $3.55
- Analyst Decision
- IPSC Strong Buy
- LTRN Strong Buy
- Analyst Count
- IPSC 5
- LTRN 1
- Target Price
- IPSC $3.33
- LTRN $25.00
- AVG Volume (30 Days)
- IPSC 1.4M
- LTRN 117.0K
- Earning Date
- IPSC 11-07-2025
- LTRN 11-14-2025
- Dividend Yield
- IPSC N/A
- LTRN N/A
- EPS Growth
- IPSC N/A
- LTRN N/A
- EPS
- IPSC N/A
- LTRN N/A
- Revenue
- IPSC $114,128,000.00
- LTRN N/A
- Revenue This Year
- IPSC $1,589.94
- LTRN N/A
- Revenue Next Year
- IPSC N/A
- LTRN N/A
- P/E Ratio
- IPSC N/A
- LTRN N/A
- Revenue Growth
- IPSC 5491.77
- LTRN N/A
- 52 Week Low
- IPSC $0.34
- LTRN $2.55
- 52 Week High
- IPSC $1.83
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- IPSC 48.92
- LTRN 36.54
- Support Level
- IPSC $0.55
- LTRN $3.75
- Resistance Level
- IPSC $0.65
- LTRN $4.09
- Average True Range (ATR)
- IPSC 0.04
- LTRN 0.29
- MACD
- IPSC -0.00
- LTRN -0.05
- Stochastic Oscillator
- IPSC 18.00
- LTRN 2.47
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.